With regard to the innate value of the stock and its current value one thing that has not be factored in, IMO, is the reference made in management's recent presentation to investors in the US (13 Jan 2014) re "Additional" licences being granted for other diseases areas expected in 2014.
This was on the same page as predicting the trials for HCV and NSCLC and I assume it was not made lightly. With new licences about to be inked the value of the stock should increase even further.
This is just more good news that is coming our way if we are to believe the presentation.
BLT Price at posting:
$1.81 Sentiment: None Disclosure: Held
